Boehringer Ingelheim posts 15pc growth in Mena
Dubai, April 15, 2014
Boehringer Ingelheim, a research-driven pharmaceutical company, has achieved a growth of 14 per cent in the Mena region in the last fiscal year.
Despite some challenges, the company succeeded in increasing its operating income and the return on net sales, said a statement.
Boehringer Ingelheim generated net sales of around €14.1 billion globally, which represents an increase of 1.4 per cent, currency-adjusted (-4.3 per cent in euro terms). This resulted in a 2.4 percentage point improvement in the return on net sales to 15 per cent, it said.
For the current financial year, the company expects net sales to remain at a comparable level to that of 2013.
Boehringer Ingelheim now employs more than 47,400 people worldwide, which is three per cent more than in the previous year.
“2013 was for Boehringer Ingelheim a year marked by many successes and some challenges,” said Professor Andreas Barner, chairman of the board of managing directors of Boehringer Ingelheim, at a press conference in Ingelheim. “We concentrated on continuing our work on the long-term development of the company.”
Boehringer Ingelheim last year successfully entered the oncology market for the targeted treatment of a specific form of lung cancer.
“We have delivered record revenue as demand for our business offerings remains high and we made strong progress in the pharmaceutical space by achieving 14 per cent growth in the Mena region,” said Karim El Alaoui, managing director, Boehringer Ingelheim Middle East, Turkey and Africa.
“These results reflect our focus on execution and long-term shareholder value as we continue to drive the strategic transformation of the company in the Middle East & Africa Region. We are delighted to be able to stay committed to improving healthcare in the region by improving patient’s lives, benefit society and the healthcare system in the region.”
In the next two years alone, Boehringer Ingelheim is planning more than 10 new launches in eight indications: diabetes, COPD, asthma, lung cancer, the rare disease idiopathic pulmonary fibrosis (IPF), Acute Meyloid leukaemia (AML) and the treatment and prevention of deep vein thrombosis and pulmonary embolism.
The company is currently working on 90 research and development projects. In the current financial year, Boehringer Ingelheim is planning to take on nine new investigational compounds in phase II clinical studies. “We will strengthen our therapeutic areas immunology and disorders of the central nervous system, CNS,” said Barner. - TradeArabia News Service